Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2004 4
2005 3
2006 3
2007 1
2009 1
2010 1
2011 2
2012 3
2013 3
2014 3
2015 5
2016 4
2017 5
2018 7
2019 11
2020 15
2021 28
2022 25
2023 27
2024 30
2025 32

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Results by year

Filters applied: . Clear all
Page 1
Ofatumumab versus Teriflunomide in Multiple Sclerosis.
Hauser SL, Bar-Or A, Cohen JA, Comi G, Correale J, Coyle PK, Cross AH, de Seze J, Leppert D, Montalban X, Selmaj K, Wiendl H, Kerloeguen C, Willi R, Li B, Kakarieka A, Tomic D, Goodyear A, Pingili R, Häring DA, Ramanathan K, Merschhemke M, Kappos L; ASCLEPIOS I and ASCLEPIOS II Trial Groups. Hauser SL, et al. N Engl J Med. 2020 Aug 6;383(6):546-557. doi: 10.1056/NEJMoa1917246. N Engl J Med. 2020. PMID: 32757523 Clinical Trial.
Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis.
Roos I, Hughes S, McDonnell G, Malpas CB, Sharmin S, Boz C, Alroughani R, Ozakbas S, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Lechner-Scott J, Kuhle J, Terzi M, Laureys G, Van Hijfte L, John N, Grammond P, Grand'Maison F, Soysal A, Jensen AV, Rasmussen PV, Svendsen KB, Barzinji I, Nielsen HH, Sejbæk T, Prakash S, Stilund MLM, Weglewski A, Issa NM, Kant M, Sellebjerg F, Gray O, Magyari M, Kalincik T; MSBase Study GroupDanish MS Registry Study Group. Roos I, et al. Among authors: ozakbas s. JAMA Neurol. 2023 Aug 1;80(8):789-797. doi: 10.1001/jamaneurol.2023.1625. JAMA Neurol. 2023. PMID: 37307006 Free PMC article.
Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.
Montalban X, Vermersch P, Arnold DL, Bar-Or A, Cree BAC, Cross AH, Kubala Havrdova E, Kappos L, Stuve O, Wiendl H, Wolinsky JS, Dahlke F, Le Bolay C, Shen Loo L, Gopalakrishnan S, Hyvert Y, Javor A, Guehring H, Tenenbaum N, Tomic D; evolutionRMS investigators. Montalban X, et al. Lancet Neurol. 2024 Nov;23(11):1119-1132. doi: 10.1016/S1474-4422(24)00328-4. Epub 2024 Sep 19. Lancet Neurol. 2024. PMID: 39307151 Clinical Trial.
Explainable time-to-progression predictions in multiple sclerosis.
D'hondt R, Dedja K, Aerts S, Van Wijmeersch B, Kalincik T, Reddel S, Havrdova EK, Lugaresi A, Weinstock-Guttman B, Mrabet S, Lalive P, Kermode AG, Ozakbas S, Patti F, Prat A, Tomassini V, Roos I, Alroughani R, Gerlach O, Khoury SJ, van Pesch V, Sá MJ, Prevost J, Spitaleri D, McCombe P, Solaro C, van der Walt A, Butzkueven H, Laureys G, Sánchez-Menoyo JL, de Gans K, Al-Asmi A, Deri N, Csepany T, Al-Harbi T, Carroll WM, Rozsa C, Singhal B, Hardy TA, Ramanathan S, Peeters L, Vens C; MSBase Study Group. D'hondt R, et al. Among authors: ozakbas s. Comput Methods Programs Biomed. 2025 May;263:108624. doi: 10.1016/j.cmpb.2025.108624. Epub 2025 Feb 6. Comput Methods Programs Biomed. 2025. PMID: 39965473
Disease Activity in Pregnant and Postpartum Women With Multiple Sclerosis Receiving Ocrelizumab or Other Disease-Modifying Therapies.
Yeh WZ, Van Der Walt A, Skibina OG, Kalincik T, Alroughani R, Kermode AG, Fabis-Pedrini MJ, Carroll WM, Lechner-Scott J, Boz C, Ozakbas S, Buzzard K, Habek M, John NA, Prat A, Girard M, Duquette P, Baghbanian SM, Hodgkinson S, Van Pesch V, Laureys G, Willekens B, Prevost J, Foschi M, De Gans K, Horakova D, Havrdova EK, Karabudak R, Patti F, Mccombe PA, Maimone D, Altintas A, Ampapa R, Spitaleri D, Gerlach OHH, Sa MJ, Hughes S, Gouider R, Mrabet S, Macdonell RA, Turkoglu R, Cartechini E, Al-Asmi A, Soysal A, Oh J, Muros-Le Rouzic E, Guye S, Pasquarelli N, Butzkueven H, Jokubaitis VG; MSBase Study Group. Yeh WZ, et al. Among authors: ozakbas s. Neurol Neuroimmunol Neuroinflamm. 2024 Nov;11(6):e200328. doi: 10.1212/NXI.0000000000200328. Epub 2024 Oct 23. Neurol Neuroimmunol Neuroinflamm. 2024. PMID: 39442037 Free PMC article.
Standardized Definition of Progression Independent of Relapse Activity (PIRA) in Relapsing-Remitting Multiple Sclerosis.
Müller J, Sharmin S, Lorscheider J, Ozakbas S, Karabudak R, Horakova D, Weinstock-Guttman B, Shaygannejad V, Etemadifar M, Alroughani R, Patti F, Eichau S, Prat A, Lugaresi A, Tomassini V, Kermode AG, Amato MP, Turkoglu R, Altintas A, Buzzard K, Soysal A, van der Walt A, Butzkueven H, Blanco Y, Gerlach O, Khoury SJ, Barnett M, John N, Lechner-Scott J, Foschi M, Surcinelli A, van Pesch V, Prevost J, Sa MJ, Maimone D, D'hooghe M, Hughes S, Hodgkinson S, McGuigan C, Cartechini E, Taylor B, Spitaleri D, Slee M, McCombe P, Yamout B, Benkert P, Kuhle J, Kappos L, Roos I, Kalincik T; MSBase Study Group; Havrdova EK, Girard M, Duquette P, Fabis-Pedrini M, Carroll WM, Skibina O, Gouider R, Mrabet S, Ramo-Tello C, Solaro C, Habek M, Van Wijmeersch B, Ampapa R, Macdonell R, Oreja-Guevara C, de Gans K, Laureys G, Oh J, Garber J, Gray O, Agüera-Morales E, Sanchez-Menoyo JL, Castillo-Triviño T, Grigoriadis N, Petersen T, Hardy TA, Vucic S, Reddel S, Ramanathan S, Al-Asmi A, Simu M, Baghbanian SM, Poehlau D, Al-Harbi T, Rojas JI, Deri N, Lalive P, Cambron M, Csepany T, Shuey N, Willekens B, Shaw C, Decoo D, Massey J, Yaldizli Ö, Derfuss T, Granziera C. Müller J, et al. Among authors: ozakbas s. JAMA Neurol. 2025 Jun 1;82(6):614-625. doi: 10.1001/jamaneurol.2025.0495. JAMA Neurol. 2025. PMID: 40227706
Prevalence of Progression Independent of Relapse Activity and Relapse-Associated Worsening in Patients With AQP4-IgG-Positive NMOSD.
Siriratnam P, Huda S, Van Der Walt A, Sanfilippo PG, Sharmin S, Foong YC, Yeh WZ, Zhu C, Khoury SJ, Csepany T, Willekens B, Etemadifar M, Ozakbas S, Nytrova P, Altintas A, Al-Asmi A, Ramo-Tello CM, Laureys G, Patti F, Horakova D, Foschi M, Boz C, Mccombe PA, Turkoglu R, Lechner-Scott J, Roos I, Kalincik T, Jokubaitis VG, Butzkueven H, Monif M; for MSBase. Siriratnam P, et al. Among authors: ozakbas s. Neurology. 2024 Dec 24;103(12):e209940. doi: 10.1212/WNL.0000000000209940. Epub 2024 Nov 19. Neurology. 2024. PMID: 39561307
First-year treatment response predicts the following 5-year disease course in patients with relapsing-remitting multiple sclerosis.
Toscano S, Spelman T, Ozakbas S, Alroughani R, Chisari CG, Lo Fermo S, Prat A, Girard M, Duquette P, Izquierdo G, Eichau S, Grammond P, Boz C, Kalincik T, Blanco Y, Buzzard K, Skibina O, Sa MJ, van der Walt A, Butzkueven H, Terzi M, Gerlach O, Grand'Maison F, Foschi M, Surcinelli A, Barnett M, Lugaresi A, Onofrj M, Yamout B, Khoury SJ, Prevost J, Lechner-Scott J, Maimone D, Amato MP, Spitaleri D, Van Pesch V, Macdonell R, Cartechini E, de Gans K, Slee M, Castillo-Triviño T, Soysal A, Sanchez-Menoyo JL, Laureys G, Van Hijfte L, McCombe P, Altintas A, Weinstock-Guttman B, Aguera-Morales E, Etemadifar M, Ramo-Tello C, John N, Turkoglu R, Hodgkinson S, Besora S, Van Wijmeersch B, Fernandez-Bolaños R, Patti F; MSBase Study Group. Toscano S, et al. Among authors: ozakbas s. Neurotherapeutics. 2025 Mar;22(2):e00552. doi: 10.1016/j.neurot.2025.e00552. Epub 2025 Feb 17. Neurotherapeutics. 2025. PMID: 39965993 Free PMC article.
Effectiveness of cladribine compared to fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting multiple sclerosis.
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, Alroughani R, Eichau Madueño S, Boz C, van der Walt A, Butzkueven H, Buzzard K, Skibina O, Foschi M, Grand'Maison F, John N, Grammond P, Terzi M, Prévost J, Barnett M, Laureys G, Van Hijfte L, Luis Sanchez-Menoyo J, Blanco Y, Oh J, McCombe P, Ramo Tello C, Soysal A, Prat A, Duquette P, Yamout BI, Khoury S, van Pesch V, Macdonell R, José Sá M, Slee M, Kuhle J, Maimone D, Spitaleri D, Willekens B, Asmi AA, Tallantyre E, Robertson NP, Coles A, L Brown JW, Kalincik T. Roos I, et al. Among authors: ozakbas s. Mult Scler. 2024 Aug;30(9):1163-1175. doi: 10.1177/13524585241267211. Epub 2024 Aug 1. Mult Scler. 2024. PMID: 39087208
181 results